GLP-1 and obesity: a bariatric surgeon's perspective

A bariatric surgeon with thousands of weight loss operations to his name deciding to take a GLP-1 medication himself is, in itself, a powerful statement. Dr. Terry Simpson, a weight loss surgery specialist and active medical communicator on social media, has spent years fighting nutritional misinformation and today explains in detail how these medications work, what distinguishes them from surgery, and why diet quality still fundamentally matters.

From the Gila monster to Ozempic: decades in the making

The first GLP-1 agonists were developed from the venom of the Gila monster lizard, studied in Arizona in the 1990s for its properties in controlling blood sugar in diabetics. Native GLP-1 lasts only about two minutes in the body. Byetta (exenatide), the first drug of this class, was approved in 2005. Since then, researchers extended the half-life of these compounds: semaglutide (Ozempic/Wegovy) has a half-life of about one week; tirzepatide (Zepbound), about five days. That extension not only improved diabetic control but produced clinically significant weight loss. There is more than 20 years of market data on these drugs, not five.

Food noise and why willpower is not enough

Simpson describes food noise as a constant mental state of preoccupation and obsession with food that most people with obesity do not even know they have until it is gone. Twelve hours after his first tirzepatide injection, he noticed something had changed in his brain. He compares it to the silence experienced when leaving a noisy city after years of living in it.

This concept is key to understanding why willpower is not the determining factor in obesity: food noise is biological, not moral. Obesity is a chronic disease, recognized as such by the WHO since 1994, and GLP-1s act directly on the hypothalamic mechanisms that generate it. These same mechanisms also modulate the reward system for tobacco, alcohol, and other substances.

Bariatric surgery vs. GLP-1: are surgeons becoming obsolete?

A colleague of Simpson's warned him ten years ago that GLP-1s would surpass bariatric surgery. He dismissed the idea. Today he acknowledges she was right. Surgery remains valuable for severe obesity cases with more than 200 pounds of excess weight, but for the majority of typical candidates, GLP-1s produce equivalent or superior results with lower risk. The obesity curve, which kept climbing for decades despite better operations and diets, is beginning to flatten and reverse because of these medications. Currently, one in eight Americans has taken or is taking a GLP-1.

The Mediterranean diet: why it still matters

Simpson remains a firm advocate for diet quality, including for GLP-1 users. His own data on bariatric patients showed that those with high Mediterranean adherence scores (5 to 9 out of 9) maintained weight loss at five years. Those scoring below 4 tended to regain it. The Mediterranean diet is not a geographic diet: it is a pattern of high vegetable, fruit, whole grain, legume, olive oil, and fish intake, with little red meat. You can follow it eating Filipino, Indian, or Finnish cuisine.

Real risks and the danger of compounded GLP-1s

The most documented adverse effects are gastrointestinal: constipation, nausea, and delayed gastric emptying. Simpson notes that 80% of GLP-1 complications seen in emergency rooms come from unapproved compounded versions whose doses are unverified and quality varies enormously. The recommendation is clear: always use FDA-approved products (Ozempic, Wegovy, Zepbound) and stay well hydrated with adequate dietary fiber.

Cardiovascular health and the statin lesson

Simpson has familial hypercholesterolemia: his father had a heart attack at 55 and lived to 98 on statins; his mother refused to take them and developed vascular dementia at 85. That personal history clearly illustrates the evidence: treating elevated cholesterol early protects the brain and heart long-term. Simpson combines tirzepatide, rosuvastatin, and ezetimibe to keep his LDL in the 40s and his ApoB at 45-46.

Conclusion

GLP-1s are not a shortcut or a magic solution — they are the most effective available treatment for a real chronic disease with a biological basis. Their impact extends beyond weight: they reduce cardiovascular risk, dementia, sleep apnea, and certain cancers. Used with medical supervision alongside a quality diet, they represent one of the most important pharmacological advances of this century.